Patients in the recurrence group showed increased expression of TLR1, TLR6 and TLR8 receptors, so that NOD‐like and TNFα signaling were increased (protective CML microenvironment) [22]. This evidence concerns the gene TLR6 and chronic myelogenous leukemia, BCR-ABL1 positive.